Torrent Pharmaceuticals is back in the spotlight after JPMorgan upgraded the stock to Overweight and lifted its price target ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Indian benchmark indices, Sensex and Nifty, traded lower on Monday, dragged by concerns over the ongoing tension in the ...

In early trading on Monday, the Dow Jones Industrial Average rose 95.63 points, or 0.23 per cent, to 42,302.45, the S&P 500 ...

A humorous look at the companies that caught our eye, for better or worse, this week ...

FacebookTweetPin The prospects of a ceasefire in the Middle East have dimmed after a series of comments by President Donald [ ...

Renewed concerns about an escalation of risks in the Middle East and weak economic data drove stocks down as bonds rose, with ...

Meta Platforms (NASDAQ: META) stock rose 0.7%, with investors impressed with the Facebook owner’s $14.8 billion investment in Scale AI and hiring of the data-labeling startup’s CEO.

Fair Value Estimate for Eli Lilly. With its 2-star rating, we believe Lilly stock is overvalued compared with our long-term fair value estimate of $650 per share, an increase from $620 as a result ...

Eli Lilly (NYSE: LLY) fourth-quarter performance exceeded the street expectations, with the company delivering adjusted earnings of $5.32 per share versus the projected $4.95. Revenue came in at ...

In Q4 2024, Eli Lilly's revenue grew 45%, driven by Mounjaro and Zepbound, the company's core weight-loss drugs. Non-incretin revenue grew by 20% compared to Q4 2023. "We exceeded our first-time ...

Eli Lilly (NYSE: LLY). Q4 2024 Earnings Call. Feb 06, 2025, 10:00 a.m. ET. Read More: Earn up to $845 cash back this year ...